Second Asian Consensus on Irritable Bowel Syndrome

Overview

Journal J Neurogastroenterol Motil

Date 2019 Jul 23

PMID 31327218

Citations 44

Authors

Kok Ann Gwee

Sutep Gonlachanvit

Uday C Ghoshal

Andrew S B Chua

Hiroto Miwa

Justin Wu

Young-Tae Bak

Oh Young Lee

Ching-Liang Lu

Hyojin Park

Minhu Chen

Ari F Syam

Philip Abraham

Jose Sollano

Chi-Sen Chang

Hidekazu Suzuki

Xiucai Fang

Shin Fukudo

Myung-Gyu Choi

Xiaohua Hou

Michio Hongo

Affiliations

Soon will be listed here.

Abstract

Background/aims: There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely to update the Asian IBS Consensus.

Methods: Key opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology, pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process was carried out by using a modified Delphi method.

Results: Thirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-brain interaction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and upper gastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet, probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy.

Conclusions: Our consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view to holistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.

Citing Articles

The intestinal microbiota modulates the visceral sensitivity involved in IBS induced by restraint combined with tail clustering.

Deng N, Xie S, Liu Q, Peng H, Fang L, Shen J Front Cell Infect Microbiol. 2025; 15:1549617.

PMID: 40051709 PMC: 11882872. DOI: 10.3389/fcimb.2025.1549617.

Anxiety and Depression Disorders in Vietnamese Patients With Irritable Bowel Syndrome: A Cross-Sectional Clinic-Based Study.

Phan T, Tran Q, Truong X, Nguyen T JGH Open. 2025; 9(2):e70116.

PMID: 39959452 PMC: 11825372. DOI: 10.1002/jgh3.70116.

Real-world safety of linaclotide in Chinese patients with irritable bowel syndrome with constipation: a multicenter, single-arm, prospective observational study.

Xiao Y, Meng X, Luo Q, Hou X, Jin J, Zhong X Therap Adv Gastroenterol. 2025; 18:17562848251314819.

PMID: 39917729 PMC: 11800259. DOI: 10.1177/17562848251314819.

Prevalence and predictors of functional gastrointestinal disorder among the undergraduate students of Bangladesh.

Roy S, Eva F, Dev D, Roy S, Tipu S, Chowdhury S PLoS One. 2024; 19(12):e0315687.

PMID: 39693324 PMC: 11654983. DOI: 10.1371/journal.pone.0315687.

The Role of the Gut Microbiota in Individuals with Irritable Bowel Syndrome: A Scoping Review.

Nagamine T Medicina (Kaunas). 2024; 60(11).

PMID: 39597080 PMC: 11596400. DOI: 10.3390/medicina60111895.

References

Tandon R, Prasad N, Gupta M, Tandon B . Stool weights and transit time in North Indians. J Assoc Physicians India. 1976; 24(12):807-10. View

Houghton L, Foster J, Whorwell P . Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000; 14(6):775-82. DOI: 10.1046/j.1365-2036.2000.00762.x. View

Lu C, Chen C, Chang F, Chang S, Kang L, Lu R . Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15(8):925-30. DOI: 10.1046/j.1440-1746.2000.02230.x. View

Shah S, Abraham P, Mistry F . Effect of cold pressor test and a high-chilli diet on rectosigmoid motility in irritable bowel syndrome. Indian J Gastroenterol. 2000; 19(4):161-4. View

Spiller R, Jenkins D, Thornley J, Hebden J, Wright T, Skinner M . Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000; 47(6):804-11. PMC: 1728147. DOI: 10.1136/gut.47.6.804. View

Masud M, Hasan M, Khan A . Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior. Am J Gastroenterol. 2001; 96(5):1547-52. DOI: 10.1111/j.1572-0241.2001.03760.x. View

Shah S, Bhatia S, Mistry F . Epidemiology of dyspepsia in the general population in Mumbai. Indian J Gastroenterol. 2001; 20(3):103-6. View

Chang L, Lee O, Naliboff B, Schmulson M, Mayer E . Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol. 2002; 96(12):3341-7. DOI: 10.1111/j.1572-0241.2001.05336.x. View

Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A . Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002; 122(7):1778-83. DOI: 10.1053/gast.2002.33579. View

10.

Hu W, Wong W, Lam C, Lam K, Hui W, Lai K . Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002; 16(12):2081-8. DOI: 10.1046/j.1365-2036.2002.01377.x. View

11.

Gwee K, Collins S, Read N, Rajnakova A, Deng Y, GRAHAM J . Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003; 52(4):523-6. PMC: 1773606. DOI: 10.1136/gut.52.4.523. View

12.

Kellow J, Lee O, Chang F, Thongsawat S, Mazlam M, Yuen H . An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003; 52(5):671-6. PMC: 1773630. DOI: 10.1136/gut.52.5.671. View

13.

Yuan Y, Tao R, Xu B, Sun J, Chen K, Miao F . Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World J Gastroenterol. 2003; 9(6):1356-60. PMC: 4611816. DOI: 10.3748/wjg.v9.i6.1356. View

14.

Chaudhary N, TRUELOVE S . The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962; 31:307-22. View

15.

Lu C, Chen C, Lang H, Luo J, Wang S, Chang F . Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther. 2003; 18(11-12):1159-69. DOI: 10.1046/j.1365-2036.2003.01711.x. View

16.

Si J, Wang L, Chen S, Sun L, Dai N . Irritable bowel syndrome consulters in Zhejiang province: the symptoms pattern, predominant bowel habit subgroups and quality of life. World J Gastroenterol. 2004; 10(7):1059-64. PMC: 4717100. DOI: 10.3748/wjg.v10.i7.1059. View

17.

Gwee K, Wee S, Wong M, Png D . The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community. Am J Gastroenterol. 2004; 99(5):924-31. DOI: 10.1111/j.1572-0241.2004.04161.x. View

18.

Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y . Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004; 53(7):958-64. PMC: 1774093. DOI: 10.1136/gut.2003.018911. View

19.

Hamaguchi T, Kano M, Rikimaru H, Kanazawa M, Itoh M, Yanai K . Brain activity during distention of the descending colon in humans. Neurogastroenterol Motil. 2004; 16(3):299-309. DOI: 10.1111/j.1365-2982.2004.00498.x. View

20.

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S . Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. PMC: 428525. DOI: 10.1136/bmj.328.7454.1490. View